1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2015. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five years.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table Of Contents

Partnerships, Licensing, Investments and MandA Deals and Trends for 2015 in Pharmaceuticals
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Pharmaceutical and Healthcare, Global, Deals Summary 18
2.1 Pharmaceutical and Healthcare, Global, Deals Analysis, 2015 18
2.1.1 Pharmaceuticals and Healthcare, Global, Deals Analysis, 2015 by Quarter 20
2.2 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals, 2015 22
2.3 Pharmaceuticals and Healthcare, Global, by Type, Deal Values, 2015 23
2.4 Pharmaceuticals and Healthcare, Global, Top Deals, 2015 24
2.5 Pharmaceuticals and Healthcare, Top Deals, Global, Summaries, 2015 25
2.5.1 Allergan and Pfizer to Combine in USD160 Billion Deal 25
2.5.2 Teva Pharma to Acquire Generics Drug Business from Allergan for USD40.5 Billion 26
2.5.3 Actavis Raises USD21 Billion in Public Offering of Senior Notes 27
2.5.4 AbbVie Acquires Pharmacyclics 28
2.5.5 Pfizer Acquires Hospira for USD17 Billion 29
2.5.6 Danaher Acquires Pall for USD13.8 Billion 30
2.5.7 CVS Health Acquires Omnicare for USD12.9 Billion 31
2.5.8 UnitedHealth Acquires Catamaran for USD12.8 Billion 32
2.5.9 Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 32
2.5.10 AbbVie Raises USD16.7 Billion in Public Offering of Notes 34
3 Pharmaceuticals and Healthcare, Global, Top Deal Makers, 2015 35
4 Pharmaceuticals and Healthcare, Global, Deal Summary, by Type 36
4.1 Pharmaceuticals and Healthcare, Global, MandA, 2015 36
4.1.1 Pharmaceuticals and Healthcare, Global, MandA, 2015 by Quarter 37
4.1.2 Top MandA Deals in 2015 38
4.1.3 Pharmaceuticals and Healthcare, Global, MandA Deals, by Therapy Area, 2015 39
4.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, 2015 40
4.2.1 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, 2015 by Quarter 41
4.2.2 Pharmaceuticals and Healthcare, Global, IPO Deals, 2015 42
4.2.3 Top IPOs in 2015 43
4.2.4 Pharmaceuticals and Healthcare, Global, Secondary Offerings Deals, 2015 44
4.2.5 Top Secondary Offerings in 2015 45
4.2.6 Pharmaceuticals and Healthcare, Global, PIPE Deals, 2015 45
4.2.7 Top PIPE Deals in 2015 46
4.2.8 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, 2015 47
4.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, 2015 48
4.3.1 Pharmaceuticals and Healthcare, Global Debt Offerings, 2015 by Quarter 49
4.3.2 Pharmaceuticals and Healthcare, Global, Public Debt Offerings, 2015 50
4.3.3 Top Public Debt Offerings in 2015 51
4.3.4 Pharmaceuticals and Healthcare, Global, Private Debt Placements, 2015 51
4.3.5 Top Private Debt Placements in 2015 52
4.3.6 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, 2015 53
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals, 2015 54
4.4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, 2015 by Quarter 55
4.4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, 2015 57
4.4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payments and Deal Value (US$ m), 2015 58
4.4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), 2015 59
4.4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2015 60
4.4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2015 61
4.4.7 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), 2015 63
4.4.8 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Deal Values, 2015 64
4.4.9 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2015 65
4.4.10 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2015 65
4.5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, 2015 66
4.5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, 2015 by Quarter 67
4.5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, 2015 68
4.5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Upfront and Milestone Payments and Deal Value (US$ m), 2015 69
4.5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), 2015 70
4.5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2015 71
4.5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2015 72
4.5.7 Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), 2015 74
4.5.8 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Deal Values, 2015 75
4.5.9 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2015 76
4.5.10 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2015 77
4.6 Pharmaceuticals and Healthcare, Global, Private Equity Deals, 2015 78
4.6.1 Pharmaceuticals and Healthcare, Global, Private Equity Deals, 2015 by Quarter 79
4.6.2 Top Private Equity Deals in 2015 80
4.6.3 Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, 2015 81
4.7 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, 2015 82
4.7.1 Pharmaceuticals and Healthcare, Global, Venture Financing Deals, 2015 by Quarter 83
4.7.2 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2015 84
4.7.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2015 85
4.7.4 Pharmaceuticals and Healthcare, Global, Venture Capital, by Therapy Area, 2015 86
4.7.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Last One Year 87
4.7.6 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, 2015 88
4.7.7 Top Venture Financing Deals in 2015 90
5 Pharmaceuticals and Healthcare, Global, Deal Summary, By Market 91
5.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, 2015 91
5.1.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, 2015 by Quarter 93
5.1.2 Oncology - Deals of the Year 94
5.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, 2015 98
5.2.1 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, 2015 by Quarter 100
5.2.2 Central Nervous System - Deals of the Year 101
5.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, 2015 106
5.3.1 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, 2015 by Quarter 108
5.3.2 Infectious Disease - Deals of the Year 109
5.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, 2015 113
5.4.1 Pharmaceuticals and Healthcare, Global, Immunology Deals, 2015 by Quarter 115
5.4.2 Immunology - Deals of the Year 116
5.5 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, 2015 119
5.5.1 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, 2015 by Quarter 121
5.5.2 Cardiovascular - Deals of the Year 122
5.6 Pharmaceuticals and Healthcare, Global, Metabolic Disorders Deals, 2015 125
5.6.1 Pharmaceuticals and Healthcare, Global, Metabolic Disorders Deals, 2015 by Quarter 127
5.6.2 Metabolic Disorders - Deals of the Year 128
5.7 Pharmaceuticals and Healthcare, Global, Gastrointestinal Deals, 2015 131
5.7.1 Pharmaceuticals and Healthcare, Global, Gastrointestinal Deals, 2015 by Quarter 133
5.7.2 Gastrointestinal - Deals of the Year 134
6 Pharmaceuticals and Healthcare, Deal Summary, By Geography 137
6.1 Pharmaceuticals and Healthcare, North America Region, Deals, 2015 137
6.1.1 Pharmaceuticals and Healthcare, North America Region, Deals, 2015 by Quarter 139
6.1.2 North America - Deals of the Year 140
6.2 Pharmaceuticals and Healthcare, European Region Deals, 2015 146
6.2.1 Pharmaceuticals and Healthcare, Europe, Deals, 2015 by Quarter 148
6.2.2 Europe - Deals of the Year 149
6.3 Pharmaceuticals and Healthcare, Asia-Pacific Region, Deals, 2015 154
6.3.1 Pharmaceuticals and Healthcare, Asia-Pacific Region Deals, 2015 by Quarter 156
6.3.2 Asia-Pacific - Deals of the Year 157
6.4 Pharmaceuticals and Healthcare, Rest of the World (ROW) Deals, 2015 160
6.4.1 Pharmaceuticals and Healthcare, Rest of the World Deals, 2015 by Quarter 162
6.4.2 Rest of the World - Deals of the Year 163
7 Pharmaceuticals and Healthcare, Global, Top Financial Advisors 166
7.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, MandA, 2015 166
7.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, 2015 168
8 Further Information 170
8.1 Methodology 170
8.2 About GlobalData 171
8.3 Disclosure information 171
8.4 Disclaimer 172

1.1 List of Tables
Table 1: Pharmaceutical and Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 19
Table 2: Pharmaceuticals and Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 21
Table 3: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), 2015 23
Table 4: Pharmaceuticals and Healthcare, Top Deals, Global, 2015 24
Table 5: Pharmaceuticals and Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (US$ m), 2015 35
Table 6: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 37
Table 7: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 38
Table 8: Pharmaceuticals and Healthcare, Global, Top MandA Deals, 2015 38
Table 9: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2015 39
Table 10: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 41
Table 11: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 42
Table 12: Pharmaceuticals and Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 43
Table 13: Pharmaceuticals and Healthcare, Global, Top IPOs, 2015 43
Table 14: Pharmaceuticals and Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 44
Table 15: Pharmaceuticals and Healthcare, Global, Top Secondary Offerings, 2015 45
Table 16: Pharmaceuticals and Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 46
Table 17: Pharmaceuticals and Healthcare, Global, Top PIPE Deals, 2015 46
Table 18: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 47
Table 19: Pharmaceuticals and Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 48
Table 20: Pharmaceuticals and Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 49
Table 21: Pharmaceuticals and Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 50
Table 22: Pharmaceuticals and Healthcare, Global, Top Public Debt Offerings, 2015 51
Table 23: Pharmaceuticals and Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 52
Table 24: Pharmaceuticals and Healthcare, Global, Top Private Debt Placements, 2015 52
Table 25: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2015 53
Table 26: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2011 - 2015 55
Table 27: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 56
Table 28: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2015 57
Table 29: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), 2015 58
Table 30: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), 2015 60
Table 31: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, 2015 62
Table 32: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Values (US$ m), 2015 64
Table 33: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payment and Deal Values (US$ m), 2015 64
Table 34: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2015 65
Table 35: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2015 65
Table 36: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 67
Table 37: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 68
Table 38: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2015 69
Table 39: Pharmaceuticals and Healthcare, Licensing Agreements, Upfront and Milestone Payments and Deal Values (US$ m), 2015 70
Table 40: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), 2015 71
Table 41: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q4 2014 - Q4 2015 73
Table 42: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Upfront and Milestone Payments and Deal Values (US$ m), 2015 75
Table 43: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payment and Deal Values (US$ m), 2015 75
Table 44: Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2015 76
Table 45: Pharmaceutical and Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2015 77
Table 46: Pharmaceuticals and Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 79
Table 47: Pharmaceuticals and Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 80
Table 48: Pharmaceuticals and Healthcare, Global, Top Private Equity Deals, 2015 80
Table 49: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 81
Table 50: Pharmaceuticals and Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 83
Table 51: Pharmaceuticals and Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 84
Table 52: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2015 85
Table 53: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2015 86
Table 54: Pharmaceutical and Healthcare, Global, Top VC Backed Companies, 2015 87
Table 55: Pharmaceuticals and Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2015 89
Table 56: Pharmaceuticals and Healthcare, Top Venture Financing Deals, Global, 2015 90
Table 57: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 92
Table 58: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 94
Table 59: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 99
Table 60: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 101
Table 61: Pharmaceuticals and Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 107
Table 62: Pharmaceuticals and Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 109
Table 63: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 114
Table 64: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 116
Table 65: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 120
Table 66: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 122
Table 67: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 126
Table 68: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 128
Table 69: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 132
Table 70: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 134
Table 71: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 138
Table 72: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 140
Table 73: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 147
Table 74: Pharmaceuticals and Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 149
Table 75: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 155
Table 76: Pharmaceuticals and Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 157
Table 77: Pharmaceuticals and Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2011 - 2015 161
Table 78: Pharmaceuticals and Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 163
Table 79: Pharmaceuticals and Healthcare, Global,, Top Financial Advisors, MandA, Number of Deals and Deal Value (US$ m), 2015 167
Table 80: Pharmaceuticals and Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2015 169

1.2 List of Figures
Figure 1: Pharmaceutical and Healthcare, Global, Number of Deals and Deal Value (US$ m), 2011- 2015 18
Figure 2: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 20
Figure 3: Pharmaceuticals and Healthcare, Global, Number Of Deals (%), 2015 22
Figure 4: Pharmaceuticals and Healthcare, Global, Deal Values (%), 2015 23
Figure 5: Pharmaceuticals and Healthcare, Global, MandA, Number of Deals and Deal Values (US$ m), 2011 - 2015 36
Figure 6: Pharmaceuticals and Healthcare, Global, MandA, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 37
Figure 7: Pharmaceuticals and Healthcare, Global, MandAs, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2015 39
Figure 8: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2011 - 2015 40
Figure 9: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 41
Figure 10: Pharmaceuticals and Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2011 - 2015 42
Figure 11: Pharmaceuticals and Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2011 - 2015 44
Figure 12: Pharmaceuticals and Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2011 - 2015 45
Figure 13: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2015 47
Figure 14: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2011 - 2015 48
Figure 15: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 49
Figure 16: Pharmaceuticals and Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2011 - 2015 50
Figure 17: Pharmaceuticals and Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2011 - 2015 51
Figure 18: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2015 53
Figure 19: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2011 - 2015 54
Figure 20: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 55
Figure 21: Pharmaceuticals and Healthcare, Global, Partnership Deals Break down (%), 2015 56
Figure 22: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2015 57
Figure 23: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), 2015 58
Figure 24: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), 2015 59
Figure 25: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, 2015 60
Figure 26: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, 2015 61
Figure 27: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), 2015 63
Figure 28: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2011 - 2015 66
Figure 29: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 67
Figure 30: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2015 68
Figure 31: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Upfront and Milestone Payments and Deal Values (US$ m), 2015 69
Figure 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), 2015 70
Figure 33: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2015 71
Figure 34: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2015 72
Figure 35: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), 2015 74
Figure 36: Pharmaceuticals and Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2011 - 2015 78
Figure 37: Pharmaceuticals and Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 79
Figure 38: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2015 81
Figure 39: Pharmaceuticals and Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2011 - 2015 82
Figure 40: Pharmaceuticals and Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 83
Figure 41: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2015 84
Figure 42: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2015 85
Figure 43: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2015 86
Figure 44: Pharmaceuticals and Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2015 88
Figure 45: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2011 - 2015 91
Figure 46: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 93
Figure 47: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2015, 2011 - 2015 98
Figure 48: Pharmaceuticals and Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 100
Figure 49: Pharmaceuticals and Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2011 - 2015 106
Figure 50: Pharmaceuticals and Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 108
Figure 51: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2011 - 2015 113
Figure 52: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 115
Figure 53: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2011 - 2015 119
Figure 54: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 121
Figure 55: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2011 - 2015 125
Figure 56: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 127
Figure 57: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2011 - 2015 131
Figure 58: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015-Q4 2015 133
Figure 59: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Value (US$ m), 2011 - 2015 137
Figure 60: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 139
Figure 61: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2011 - 2015 146
Figure 62: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 148
Figure 63: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2011 - 2015 154
Figure 64: Pharmaceuticals and Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 156
Figure 65: Pharmaceuticals and Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2011 - 2015 160
Figure 66: Pharmaceuticals and Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2015-Q4 2015 162
Figure 67: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, MandA, Number of Deals and Deal Value (US$ m), 2015 166
Figure 68: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2015 168

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.